Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Pulmonary Hypertension, September 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 43 articles: HTML format

Single Articles

1. GUEVARA YAS, Gonzaga-Costa K, Calixto GL, Diaz LC, et al
   Therapeutic effects of trans-3-methoxy-beta-nitrostyrene in rat model of monocrotaline-induced pulmonary hypertension.
   Eur J Pharmacol. 2026 Sep 4:179310. doi: 10.1016/j.ejphar.2026.179310.
   PubMed    
   Abstract available
   
   

2. LI Z, Xu X, Li J, Fang Y, et al
   Artificial Intelligence in Pulmonary Hypertension: Current State and Future Prospects.
   Rev Cardiovasc Med. 2026;27:48114.
   PubMed    
   Abstract available
   
   

3. EL KAISSI J, Laoutid J
   Continuous Spinal Anesthesia in a High-Risk Patient With Pulmonary Hypertension Undergoing Hip Fracture Repair: A Case Report.
   Case Rep Anesthesiol. 2026;2026:5262622.
   PubMed    
   Abstract available
   
   

4. HAN DS, Wei MM, Liu RX, Ma YG, et al
   [Effects of Gualou Xiebai Banxia Decoction on pulmonary vascular remodeling in rats with hypoxic pulmonary hypertension].
   Zhongguo Zhong Yao Za Zhi. 2026;51:4723-4733.
   PubMed    
   Abstract available
   
   

5. CANTOR HJ, Zhu D, Li Z, Hu S, et al
   Therapeutic Reversal of PH-HFpEF via Lung Spheroid Cell Exosomes.
   ACS Nano. 2026;20:23871-23883.
   PubMed    
   Abstract available
   
   

6. HENEMA MMF, Brown SC, Smit FE, Botes L, et al
   An analysis of imaging modalities to assess the right and left heart in pulmonary hypertension with left-to-right shunts.
   Cardiovasc J Afr. 2026;37:345-353.
   PubMed    
   Abstract available
   
   

7. AVERJANOVAITE V, Gumbiene L, Zakarkaite D, Laukyte-Sleniene M, et al
   Pulmonary Function and Exercise-Based Assessments for the Detection of Pulmonary Hypertension in Fibrotic Interstitial Lung Disease.
   Pulm Circ. 2026;16:e70402.
   PubMed    
   Abstract available
   
   

8. NISHIYAMA M, Okada T, Teranaka W, Naruko T, et al
   Chronic thromboembolic pulmonary hypertension: towards an etiology-oriented conceptual framework.
   Front Med (Lausanne). 2026;13:1910552.
   PubMed    
   Abstract available
   
   

9. WU M, Su H, Sun X, Gong S, et al
   Diffusing Capacity of the Lung for Carbon Monoxide and the Risk of All-Cause Mortality in Patients With Pulmonary Hypertension Caused by Fibrosing Mediastinitis: A Multicenter Cohort Study.
   Pulm Circ. 2026;16:e70401.
   PubMed    
   Abstract available
   
   

10. WICK C, Lichtblau M, Titz A, Muller J, et al
    Effect of low-flow oxygen therapy on 6 minute walk test in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a randomized non-inferiority crossover trial.
    Eur Heart J Open. 2026;6:oeag125.
    PubMed    
    Abstract available
    
    

11. LUO L, Wang X, Huang K, Yang Y, et al
    Anomalous origin of the left coronary artery from the pulmonary artery with coronary artery fistula in an adult presenting with cardiomegaly, abnormal electrocardiogram, myocardial perfusion defect and pulmonary hypertension: a case report.
    Front Cardiovasc Med. 2026;13:1844272.
    PubMed    
    Abstract available
    
    

12. SUN Y, Ding R, Su X, Qin L, et al
    Pulmonary Hypertension Molecular Switch: HIF Signaling Pathway.
    Pulm Circ. 2026;16:e70385.
    PubMed    
    Abstract available
    
    

13. YAKU A, Mylvaganam RJ, Shah SJ
    Redefining systemic sclerosis-associated pulmonary hypertension as an immune-mediated vasculopathy across the cardiopulmonary circulation.
    Curr Opin Rheumatol. 2026 Sep 3. doi: 10.1097/BOR.0000000000001202.
    PubMed    
    Abstract available
    
    

14. COSTELLE A, Leewiwatwong S, Mugler JP 3rd, Mummy D, et al
    Standardized Spectral Mapping With (129)Xe Chemical Shift Imaging: Investigating Red Blood Cell Shift Heterogeneity in Pulmonary Hypertension.
    NMR Biomed. 2026;39:e70388.
    PubMed    
    Abstract available
    
    

15. HOU P, Ke M, Jiang Q, Lai N, et al
    Cerebral hypoperfusion in pulmonary arterial hypertension: Association with right ventricular dysfunction and risk stratification.
    Ther Adv Respir Dis. 2026;20:17534666261485141.
    PubMed    
    Abstract available
    
    

16. BIKOU O, Halouani A, Sun Y, Bisserier M, et al
    MicroRNA-224 orchestrates BMP and TGFbeta signaling and is a therapeutic target in preclinical pulmonary arterial hypertension.
    Sci Transl Med. 2026;18:eaef6676.
    PubMed    
    Abstract available
    
    

17. YE P, Zhu L, Chu P, Wang D, et al
    Secretory Carrier Membrane Protein 3 Knockdown Attenuates Hypoxic Pulmonary Hypertension Potentially Involving WW Domain-Containing E3 Ubiquitin Protein Ligase 1.
    Biochem Genet. 2026 Sep 2. doi: 10.1007/s10528-026-11446.
    PubMed    
    Abstract available
    
    

18. ZOU Y, Ahmad A, Zhang S, Wang Y, et al
    Repurposing SGLT2 inhibitors in pulmonary arterial hypertension: A multi-center longitudinal pilot study demonstrating favorable effects on risk profile and ventricular coupling.
    Ther Adv Respir Dis. 2026;20:17534666261479969.
    PubMed    
    Abstract available
    
    

19. CHANGELA S, Hadidchi R, Madan J, Henry SS, et al
    Elevated risk of first-time pulmonary hypertension among COVID-19 survivors: a 4.5-year longitudinal study.
    ERJ Open Res. 2026;12:01768-2025.
    PubMed    
    Abstract available
    
    

20. LI Y, Huang J, Zhang X, Liu Y, et al
    Internet-Based home care education for children with pulmonary hypertension: a public health perspective.
    Front Pediatr. 2026;14:1759723.
    PubMed    
    Abstract available
    
    

21. SAWCZAK F, Kukfisz A, Dudek M, Straburzynska-Migaj E, et al
    Relationship between right heart catheterization and exercise testing in heart failure patients with and without pulmonary hypertension - cross-sectional study.
    Front Cardiovasc Med. 2026;13:1812393.
    PubMed    
    Abstract available
    
    

22. LU GF, Guo Y, Geng F
    Circular RNAs regulate the progression of pulmonary hypertension through distinct roles and mechanisms.
    J Pharmacol Exp Ther. 2026;393:104987.
    PubMed    
    Abstract available
    
    

23. KRUTHOF J, De Haes J
    Changing paradigm in pulmonary hypertension during pregnancy: from universal contraindication to individualized management.
    Int J Obstet Anesth. 2026;68:105272.
    PubMed    
    
    
    

24. JIANG S, Tian L, Qu J, Hong Y, et al
    Human iPSC-Derived Vascularised Lung Organoids for Modelling COPD and Pulmonary Hypertension.
    Cell Prolif. 2026 Sep 1:e70273. doi: 10.1111/cpr.70273.
    PubMed    
    Abstract available
    
    

25. MILANOVA-ILIEVA D, Ketev K, Karavelikova I, Chochkova-Bukova L, et al
    Long-term management of a child with aortopulmonary septal defect and Eisenmenger syndrome: a 6-year follow-up case study.
    Folia Med (Plovdiv). 2026;68.
    PubMed    
    Abstract available
    
    

26. LI W, Ke X, Ma J, Jin R, et al
    Patients' perspectives on pulmonary rehabilitation for pulmonary hypertension in high-altitude areas: a mixed-methods study.
    Front Public Health. 2026;14:1869309.
    PubMed    
    Abstract available
    
    

27. KIM NY, Im DJ, Hong YJ, Lee JW, et al
    Sequential Changes in Right Ventricular Straein During the Development of Pulmonary Hypertension Assessed With Magnetic Resonance Feature Tracking: An Animal Study.
    Korean J Radiol. 2026 Sep 1. doi: 10.3348/kjr.2026.0774.
    PubMed    
    Abstract available
    
    

28. MADONNA R, Del Boccio P, Borghini A, Alberti M, et al
    Sodium-glucose cotransporter 2 inhibitors are associated with reduced circulating activin A and modulation of BMP/activin signaling in ischemic cardiomyopathy with high echocardiographic probability of pulmonary hypertension.
    Geroscience. 2026 Aug 31. doi: 10.1007/s11357-026-02497.
    PubMed    
    Abstract available
    
    

29. CHEN W, Dong Y, Shi Q, Meng H, et al
    Multi-omics and experimental validation reveal the proliferative mechanism of ACSL4 in pulmonary hypertension and identify potential FDA-approved drugs via in silico screening.
    Vascul Pharmacol. 2026;164:107694.
    PubMed    
    Abstract available
    
    

30. LI X, Wu L, Liu X, Li P, et al
    Warfarin Dose Adjustment During Rifampicin Therapy: A Case Report with Practical Monitoring Implications.
    J Vis Exp. 2026;.
    PubMed    
    Abstract available
    
    

31. ZHUANG S, Zheng L, Wang X, Pu J, et al
    The clinical characteristics and risk factors of pulmonary arterial hypertension in primary Sjogren disease: a single-center retrospective study.
    Clin Rheumatol. 2026;45:5615-5624.
    PubMed    
    Abstract available
    
    

32. PARK HW, Park Y, Lee JJ, Ju JH, et al
    Clinical characteristics and factors associated with progressive pulmonary fibrosis in patients with systemic sclerosis-associated interstitial lung disease.
    Clin Rheumatol. 2026;45:5585-5595.
    PubMed    
    Abstract available
    
    

33. MOURA-FERREIRA S, Milani M, Dhont S, L'Hoyes W, et al
    Risk stratification in aortic stenosis: exercise haemodynamics to refine risk in early cardiac damage stages.
    Eur Heart J Cardiovasc Imaging. 2026;27:1686-1698.
    PubMed    
    Abstract available
    
    

34. TEIXEIRA M, Couto DS, Oliveira MI, Aires I, et al
    Transpulmonary proteomic gradient analysis in women with pulmonary arterial hypertension associated with systemic sclerosis.
    J Proteomics. 2026;331:105703.
    PubMed    
    Abstract available
    
    

35. BARBERO C, Loforte A, Scala V, Trompeo AC, et al
    Emergent simultaneous cesarean section and maternal cardiac surgery.
    Heart Lung. 2026;79:102820.
    PubMed    
    Abstract available
    
    

36. GOWDA N, Lal Negi S, Puri GD, Kumar R, et al
    Net Atrioventricular Compliance: A Determinant of Pulmonary Artery Pressure in Patients Undergoing Mitral Valve Replacement for Severe Mitral Stenosis.
    Semin Cardiothorac Vasc Anesth. 2026;30:183-190.
    PubMed    
    Abstract available
    
    

37. KADOTA M, Yagi S, Akagi S, Kasahara S, et al
    Treat-and-repair Strategy for Atrial Septal Defect with Eisenmenger Syndrome due to Pulmonary Arterial Hypertension.
    Intern Med. 2026;65:2346-2351.
    PubMed    
    Abstract available
    
    

38. AL-QAZAZI R, Emon IM, Potus F, Martin AY, et al
    Germline and somatic variants in DNMT3A and other clonal haematopoiesis of indeterminate potential genes contribute to pulmonary arterial hypertension.
    Eur Heart J. 2025 Aug 29:ehaf611. doi: 10.1093.
    PubMed    
    Abstract available
    
    

39. D'ALTO M, Cangiano N, Orlando A, Argiento P, et al
    Multicenter invasive validation of the Venous Excess Ultrasound Score (VExUS) in patients referred for pulmonary hypertension.
    Chest. 2026 Aug 29:S0012-3692(26)06526-8. doi: 10.1016/j.chest.2026.
    PubMed    
    Abstract available
    
    

40. ZHANG J, Li Y, He M, Tan J, et al
    PUS7-Mediated Pseudouridylation of TGFBI Drives Vascular Remodeling in Pulmonary Hypertension.
    Circulation. 2026 Sep 1. doi: 10.1161/CIRCULATIONAHA.126.080714.
    PubMed    
    Abstract available
    
    

41. LYNCH PT, Makkapati S, George JC, Vaidya A, et al
    Left Circumflex Coronary-Pulmonary Arterial Collaterals in Chronic Thromboembolic Pulmonary Hypertension.
    Circulation. 2026;154:872.
    PubMed    
    
    
    

42. ERSBOLL MK, Kjaergaard J, Waidtlow K, Kober L, et al
    Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: The DAPAH randomized controlled trial.
    J Heart Lung Transplant. 2026 Aug 31:S1053-2498(26)01987.
    PubMed    
    Abstract available
    
    

43. ZHANG H, Wang Q, Liang M, Chen X, et al
    Pulmonary Denervation for Heart Failure-Related Pulmonary Hypertension.
    N Engl J Med. 2026 Aug 30. doi: 10.1056/NEJMoa2609056.
    PubMed    
    Abstract available